Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dollar General Corp. (DG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance

Dollar General Corp.Trade
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade

Price performance (Past 24H)

Key statistics

Dollar General Corp. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Dollar General Corp. trades at $124.94 (market cap $27.42B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.1× Dollar General Corp.'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.

DGTAK
Market Cap
$27.42B$58.74B
Volume
2,291,5173,110,994
Sector
Consumer StaplesHealth
52-Week High
$156.26$19.05
52-Week Low
$95.94$13.23
Typical Hold Time
59 Days0 Days
Enterprise Value
$41.60B$86.65B
Dividend Yield
1.9%3.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dollar General Corp.

Dollar General (DG) trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong fundamentals with a P/E of 16.14 and P/S of 0.63, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $2.48 surpassing the $2.01 expectation. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart, supporting growth initiatives.

The outlook is cautiously optimistic, with a consensus price target of $137.27 offering ~12% upside. Key opportunities include margin improvement from operational initiatives, while risks involve competitive pressures and potential consumer spending softness. Analyst sentiment is predominantly buy-rated (55.77%), though recent insider selling and mixed technical indicators warrant monitoring.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DG

No sentiment data available yet.

TAK
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG →

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →